Skip to content Skip to sidebar Skip to footer

Simulations Plus (NASDAQ:SLP) is set to announce its fourth-quarter earnings data after the market closes on Wednesday, October 23rd. Analysts are anticipating earnings of $0.04 per share for the quarter. The company’s shares opened at $31.50 on Wednesday, experiencing a 0.7% decline. Simulations Plus has a 12-month low of $29.37 and a 12-month high of $51.22. Its fifty-day simple moving average stands at $33.65, while the 200-day simple moving average is $41.18. With a market capitalization of $630.25 million, the company has a PE ratio of 65.63 and a beta of 0.69.

In recent news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock on Thursday, August 1st, at an average price of $39.63 per share, resulting in a total transaction value of $792,600. Following the sale, Woltosz now owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This represents a 0.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission.

Over the past 90 days, insiders have sold a total of 60,750 shares of Simulations Plus stock, amounting to $2,145,055. Currently, company insiders own 20.90% of the stock.

Simulations Plus, Inc. develops drug discovery and development software worldwide, specializing in modeling and simulation, as well as prediction of molecular properties using artificial intelligence and machine learning-based technology. The company operates through two segments: Software and Services. Its product offerings include GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals, and DDDPlus and MembranePlus simulation products.